Topic Archives: glioblastoma

Comments

  • Avatar

    In regards to Glioblastoma NWBO, deep in OTC penny land, is hopefully close to P3 results. Anecdotal comments suggest ...

  • Avatar

    $DFFN UW CHARLOTTESVILLE, Va., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (Diffu...

  • SoGiAm

    $DFFN bid os - https://finviz.com/quote.ashx?t=DFFN #Diffusio2n http://www.diffusionpharma.com/scientific-advisory-boar...

  • Avatar

    $DMPI LONG 29-Dec-2017:08:43:00, DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent G...

  • Avatar

    $DPMI 26-Dec-2017:05:30:00, DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblas...

  • SoGiAm

    $VBLT np - New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect o...

  • SoGiAm

    $MBRX 1/2p - Please be advised, the Moleculin Biotech, Inc. (Nasdaq: MBRX) management team including, Walter Klemp, CE...

  • SoGiAm

    $TRIL - Society for Neuro-Oncology 22nd Annual Meeting poster: http://s2.q4cdn.com/772010778/files/doc_presentations/20...

  • Avatar

    $STML LONG NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage b...

  • Avatar

    $ STML Long More News 09-Nov-2017:16:01:00, Stemline Therapeutics Reports Third Quarter 2017 Financial Result...

  • SoGiAm

    $TRIL - November 18, 2017 05:00 PM PST San Francisco, CA Presenter: Zezhou Wang, Ph.D., Trillium Research Scientist h...

  • Avatar

    NP $ VBLT 07:01 VBLT Vascular Biogenics announces that the EMA has designated ofranergene obadenovec (VB-11...

  • Avatar

    NP $ MBRX heflyonthewall.com: Moleculin announces strategic collaboration to develop immune stimulation drug Molec...

  • Avatar

    Michael, Why have you not discussed the phase 3 results of Northwest Bio on the most deadly form of glioblastoma?...

  • Avatar

    $ABIO and others Thx Levbrans. Re: ABIO. I have a morbidly obese position with avg price of 2.00, so I'm down about 30...

  • Avatar

    $ABIO $BLPH $VBLT Just added heavily to all 3 positions and now OW. ABIO: Briefly, they are developing the Beta ...

  • Avatar

    $VBLT. Thanks, Doc. To be clear about this, I'm not questioning your medical knowledge or investment advice, both of...

  • Avatar

    vanderwall7, you said there has never been a cure of a glioblastoma multiforma tumor. I've been following a doctor in Ho...

  • Avatar

    There has been a glioblastoma multiforma that was held in remission for 5 years, using a low-temperature water extract o...

  • Avatar

    One of the example he used was a GBM that went into remission. To my knowledge there has never been a cure of a GBM whi...

  • SoGiAm

    $VBLT - 2 conference presentations: http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-news&nyo=0 2017 BIO ...

  • Avatar

    $ VBLT. Long VBL Therapeutics announces VB-111 phase 2 data presented at ASCO VBL Therapeutics announced the present...

  • Avatar

    $VBLT Doc, here is a transcript of their CC from 2 days ago. Still looking good IMO. Re: Their GBM, they expect in...

  • Avatar

    $CLRB long Shares down on (despite?) patent news: Apr 25, 2017: Cellectar Biosciences Receives Additional U.S. Patent...

  • Avatar

    $VBLT VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences - TEL AVI...

  • Avatar

    $ VBLT Long 20-Apr-2017:16:01:00, VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigat...

  • SoGiAm

    $AGEN np - Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII $AGEN -5.5% https:...

  • Avatar

    $STML: Stemline Therapeutics Provides Update on Clinical Programs SL-401 --Patient enrollment has continued to...

  • SoGiAm

    Revolutionary approach for treating glioblastoma works with human cells News Release: For immediate use: Revolutionary...

  • Avatar

    Hi everyone, According to the trusted source: @AndyBiotech $TCON will soon release their TRC105 & Avastin 1012 mont...

  • Avatar

    $VBLT: VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study January 6, 2017 TEL AVIV, I...

  • Avatar

    Berberine. Here is what I found at LEF.Com. Berberine is an alkaloid found in various different medicinal herbs. Prob...

  • Dr. KSS MD PhD

    DB: that was among my very first questions in picking through what I CAN access on NSI-189. Some of it is proprietary, B...

  • DBMD

    $CUR I was just looking at that stock and was a little bit concerned about the possibility of causing other neural tissu...

  • SoGiAm

    $STML long - Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at t...

  • Avatar

    $AGEN: Agenus Reports Third Quarter Financial Results and Recent Highlights/Development Updates Company to host conf...

  • achandra13

    From a quick read, their focus is totally different. These are the two treatments they are actively pursuing: 1. Brai...

  • Avatar

    The most devastating aspect of $BMY's "epic failure" was that, in the trial for NSCLC as front-line therapy, Opdivo fail...

  • arch1

    ben Thank you . That makes eminent sense to me and is quite astounding that such a small sample may yield results. This ...

  • Avatar

    $VBLT -- Dr. KSS: On June 10, you said "Biggest problem is that it can only be given once" (in context of glioblastoma...

  • Dr. KSS MD PhD

    $VBLT is VBL Technologies, formerly Vascular Biogenics, an Israeli firm. I took a position because I was impressed with ...

  • arch1

    Dr KSS I don't know if you have seen this ,,,It seems to me this is worth noting on brain barrier crossing. The blood-b...

  • SoGiAm

    $KPTI nada - Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting ...

  • Dr. KSS MD PhD

    As to the discussion of Duke's modified poliovirus for glioblastoma multiforme, as best I can tell this study or its IP ...

  • Avatar

    Make that three of us. I added to my modest position yesterday. Also loved the study Glenn shared about efforts to cross...

  • arch1

    glenn Thanks for this post. My youngest son died of glioblastoma in his late forties....

  • achandra13

    $KPTI From Bens link, it does look promising for Selinexor. Unfortunately I opened my full position at the peak (~$30...

  • DBMD

    Glioblastoma is a bad dz, usually not much after 6 months of dx people were dead. This has improved some. Gamma knife us...

  • sogiam

    AGEN, AKBA, PIRS, FLKS: Extracted from: http://www.thelifesciencesreport.com/pub/na/panelists-select-19-companies-for-t...

  • Avatar

    Getting a gut feeling that AGEN is sitting on some great news coming with several strong catalysts coming into play. The...

  • sogiam

    Phase 2 Study of MEDI4736 in Patients With Glioblastoma https://clinicaltrials.gov/ct2/show/study/NCT02336165?term=MEDI...

  • sogiam

    NVCR- FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma http://...

  • Dr. KSS, MD PhD

    I entered Agenus $AGEN this past week. Since we now have evidence of efficacy on multiple fronts---genital herpes, sh...

  • Dr. KSS, MD PhD

    OK, I will honorably concede a certain measure of defeat as regards $CLDX. Its immune-tweaking agent rindopepimut, combi...

  • Avatar

    $KPTI: Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors - Presentation to Include ...

  • Vijay Panikar

    $KPTI. from leerink asco abstracts. • KPTI (OP): Ph II data for selinexor suggests single agent activity in solid...

  • Avatar

    Karyopharm (KPTI) presenting solid tumor data on Selinxor at ASCO. Promising antitumor activity was observed in abstrac...

  • Avatar

    $ZIOP: Ziopharm initiates Phase 1 gene therapy trial in brain cancer -Ziopharm Oncology (NASDAQ:ZIOP) commences a Ph...

  • Avatar

    Ok this does come from SA but it was very interesting nonetheless. It looks to be similar to Cellectis. http://seekin...

  • Avatar

    $CLDX up 15% this morning based on this FDA granting rindopepimut (Rintega(R)) Breakthrough Therapy Designation for the ...

  • Avatar

    Ok that "global stomp" in my last post should say glioblastoma! Damn auto correct!...

  • Dr. KSS, MD PhD

    Even with a CAR-T-entrained approach against the mutant EGF regions typifying glioblastoma multiforme, anti-tumor respon...

  • Dr. KSS, MD PhD

    Hi edinle....$CLDX has come up several times in the threads, but to summarize: (1) I predict phase 3 failure for rind...

  • Avatar

    Doc, If you have time, could you give us an opinion about CLDX. The pipeline includes rindopepimut, in P3 trials for gl...

  • Avatar

    Northwest Biotherapeutic (NWBO) might deserve a mention in this list. NW Bio is Developing dendritic cell-based vaccines...

  • Dr. KSS, MD PhD

    Glenn, I think you asked earlier about Northwest Biotherapeutics and its dendritic cell vaccine program for glioblastoma...

  • DBMD

    Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3) for myleodysplasia, old blood. They have competit...

  • Avatar

    Hello Dr K, according to their website this method/device already has FDA approval for and is already in use for re-cur...

  • Dr. KSS, MD PhD

    NEVER AGAIN IN THIS INCARNATION WILL YOU SEE THIS HAPPEN: a phase 3 trial for glioblastoma stopped early on unprecedent...

  • Dr. KSS, MD PhD

    Kenny: I don't mean to ruffle any feathers, but I am of little or no faith in $CLDX. Its glioblastoma program themed ...

  • Anshuman Chandra

    I had no idea so many companies are working on so many drugs. Are all of them private companies except ISIS? ISIS: ...

  • Avatar

    Some great news from AEMD dealing with brain cancer: Aethlon Medical and Exosome Sciences Expand Brain Research Disco...

  • Avatar

    This is an interesting experiment, Travis. I have two specs that I am currently playing. One is Northwest Biotherapeut...

  • karmaswimswami

    Siva: I don't mean to sound like the Herb Greenberg of Gumshoe, but I just cannot see a case for IMUC at all. It issued ...

  • Avatar

    Found this Seeking Alpha article today about Celldex and its glioblastoma vaccine (which includes Stellar's KLH), could...

  • Avatar

    Thanks for the reply AH. I used the lower range of numbers that Stellar estimated (in their investor presentation) as y...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch